A Study of Famitinib in Combination With HS-10296 in Patients With EGFR-mutant NSCLC

NCT03904823 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

58

Enrollment

INDUSTRY

Sponsor class

Conditions

EGFR-mutant Non-Small Cell Lung Cancer

Interventions

DRUG: famitinib po
DRUG: HS-10296 po

Sponsor

Jiangsu HengRui Medicine Co., Ltd.